Core business revenue grew 6% year-over-year in Q2 2026, driven by upsell and cross-sell momentum after divesting the 3P Revenue Recovery business. AI-powered solutions and platform enhancements are delivering tangible ROI, with strong guidance for margin expansion and continued ARPU growth.Based o…
Q2 2026 saw higher EPS and strong industrial growth, with major battery and transmission projects advancing. Full-year EPS guidance was raised, CapEx is trending high, and large customer contracts are driving revenue gains. Hydropower output guidance was trimmed due to dry weather.Based on IDACORP…
Shares of Karyopharm Therapeutics (KPTI) fell 69% in after-hours trading on Thursday after the biotech company reported that its drug selinexor failed to delay disease progression meaningfully in endometrial cancer in a late-stage clinical trial.What Did The Trial Show?The late-stage study tested s…
Revenue diversification accelerated as Bitcoin transactions fell to 12% of total, while subscription products like Coinbase One hit record highs. New product launches and cross-selling drove incremental trading, and Base led in stablecoin transfer volume.Based on Coinbase Global, Inc. [COIN] Q2 202…
Book value per share fell 9.6% to $20.74, driven by FX losses and a net loss from Sanmar's sale. Public investments declined in value, while private holdings like Seven Islands and BIAL showed resilience. The company remains focused on capital preservation amid ongoing global and local risks.Origin…
Q3 results met guidance, with strong Q4 growth expected from video distribution, automotive, and wearables. Major new licensees like Meta and Alibaba joined the Video Distribution Program, and share repurchase activity increased. Guidance reflects robust momentum in key growth areas.Based on Dolby…
Q2 2026 saw record revenues exceeding $950 million, driven by strong performances from INGREZZA, CRENESSITY, and the newly acquired VYKAT XR. Guidance for INGREZZA was raised, and the company remains on track for key clinical milestones in 2027, with robust financial flexibility and expanding marke…
Revenue grew 23% year-over-year with strong credit improvement, lower delinquencies, and expanding fintech partnerships. Net interest margin and fee income rose, while guidance points to continued margin expansion, loan growth, and improved credit costs in H2 2026.Based on First Internet Bancorp [I…
Q2 2026 saw strong cash flow and higher liquids sales, offsetting lower natural gas prices and volumes. Major infrastructure projects were completed, positioning for lower costs and stable production, with net debt flat and continued share buybacks planned.Original document: Advantage Energy Ltd [A…
Revenue grew 36% year-over-year to $1.5B, with bookings up 8% to $1.6B, but monetization per hour declined due to a shift toward evergreen content and algorithm changes. DAUs reached 123M, with strong international growth, while Q3 bookings are forecast to decline 14–18% year-over-year.Based on Rob…
Book value per share fell 9.6% to $20.74, driven by FX losses and a net loss from the Sanmar sale. Public investments declined in value, while private investments saw gains in BIAL and Seven Islands. The company increased its stake in IIFL Capital and completed the BIAL payment.Original document: F…
Fan demand and spending for live events are at record highs, driving double-digit growth in attendance, revenue, and AOI. International expansion, new venue acquisitions, and technology investments are fueling future growth, with strong outlooks for 2026 and 2027.Based on Live Nation Entertainment…
Q2 saw strong R2 launch momentum, record demo drives, and robust revenue growth, with improved gross profit and reduced losses. Guidance was raised for 2026 deliveries, and liquidity exceeds $14 billion, supporting continued investment in autonomy and manufacturing expansion.Based on Rivian Automot…
Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.Based on Ill…
Q2 2026 saw strong financial results, with service revenue up 6.7% and EPS beating consensus by $0.14. Enrollment growth was robust across online, ground, and hybrid platforms, while new program launches and an amended MSA position the company for continued expansion.Based on Grand Canyon Education…
Revenue and adjusted EBITDA exceeded guidance, with strong cash flow and a major customer expansion to over $10M ARR. Strategic cohorts and generative AI drove growth, while guidance for FY27 remains unchanged amid healthy demand and disciplined investment.Based on Coveo Solutions, Inc. [CVO] Q1 20…
Core EPS for Q2 2026 rose to $1.54, with year-to-date EPS at $2.97 and full-year guidance reaffirmed. Wildfire mitigation, grid hardening, and clean energy investments remain priorities, while legislative outcomes on wildfire reform and affordability pose ongoing risks.Based on Edison International…
Q2 saw 61% revenue growth to $805M, with adjusted EBITDA margin at 43% and net income more than doubling year-over-year. User growth was driven by improved retention and product enhancements, while ad revenue and engagement metrics surged across segments.Based on Reddit, Inc. [RDDT] Q2 2026 Audio T…
Q2 2026 saw 7.2% revenue growth and 12.1% EPS growth, driven by strong organic performance and disciplined cost management. Despite property pricing headwinds and increased competition, the platform delivered resilient results, expanded its share repurchase program, and maintained a positive outloo…
Q2 revenue grew 44% year-over-year to $335 million, driven by strong oncology, biopharma, and screening performance. FDA approvals, ACS guideline inclusion, and UnitedHealth coverage expanded Shield's reach to 70 million lives. Raised 2026 revenue guidance and accelerated investments in lab capacit…
